X‑Chem spin-off X-Biotix Therapeutics Completes $7 million Series A Financing
WALTHAM, Mass. April 24, 2018 – Small molecule drug discovery specialist X-Chem, Inc. (XChem) today announced that its spin-out company X-Biotix Therapeutics, Inc. (X-Biotix) has secured $7 million in a Series A financing from a group of private investors. X-Biotix, launched in 2017 out of X-Chem by Ramani Varanasi, Ph.D. and faculty members in the Department of Microbiology and Immunobiology at Harvard Medical School, plans to use the financing to advance its pipeline of novel antibiotics targeting Gram-negative bacteria. The company leverages the research of its scientific founders in essential biological pathways in bacteria and X-Chem’s DNA-encoded small molecule discovery platform.
Privacy Policy
English French Hungarian Cookie-beállítások Az Ön adatainak védelme fontos az X-Chem és leányvállalatai számára (a továbbiakban “mi” és/vagy “minket” és/vagy...
Evotec and X‑Chem Collaborate to Accelerate Early-Stage Drug Discovery
WALTHAM, Mass.; Sept. 5, 2024 – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and X-Chem, leader...
X‑Chem and Sironax Begin Neurodegenerative Disease Drug Discovery Research Partnership
WALTHAM, Mass.; Jan. 5, 2023 (Business Wire) — X-Chem (X-Chem), the global leader in DNA-encoded library (DEL) technology, today announces...
Chimie Médicinale
Anglais Français Proposer des candidats réalistes avec des décennies d’expérience et un palmarès éprouvé de succès auprès des clients Avec...
Job Opportunities
Anglais Français Notre histoire X-Chem est un pionnier de la technologie des librairies chimiques encodées dans l’ADN (DEL) depuis 2009...